Pandit R, et al. - Given the induction of weight gain, a debilitating adverse effect, in relation to most antipsychotics, researchers sought the phenotypic factors correlated with amisulpride-induced weight gain in first-episode psychosis patients. From the Optimization of Treatment and Management of Schizophrenia in Europe trial, data was collected. They performed multivariable regression models with various phenotypic variables (N=305) with absolute antipsychotic-induced weight gain (AiWG) and clinically relevant AiWG (≥7% AiWG) as outcomes. They noted an increase in body weight from 69.7 to 72.4 kg following 4 weeks of amisulpride treatment. A relatively high predisposition to AiWG was seen in unemployed first-episode patients with psychosis, especially young patients diagnosed with schizophreniform disorder. These patients should be carefully monitored and, when required, weight-reducing strategies should be implemented.